George Schmieder is a Dermatology physician affiliated with Park Avenue Dermatology. OpenAlex indexes 15 publications with 506 citations (h-index 8); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
906 Park Ave
Orange Park, FL 320734120
Telephone
904-541-0315Provider last certified this registry record 28 Jun 2022.
Clinical trials
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
30 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- GENZYME CORPORATIONProgram year20257 payments
- PFIZER INC.Program year202516 payments
- ABBVIE INC.Program year202510 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
71.7%Tetracycline-class Drug62.3%Doxycycline Hyclate100%Part D≥597 patientsCephalosporin Antibacterial5.5%Ceftriaxone sodium100%Part B, office-administered≥16 patients+ 2 more classes in this area
Sensory organs
20.4%Aminoglycoside Antibacterial20.4%Gentamicin Sulfate100%Part D≥232 patientsDermatology
4.8%Corticosteroid3%Triamcinolone Acetonide53%Triamcinolone acetonide47%Part D + Part B≥17 patientsInterleukin-4 Receptor alpha Antagonist1.8%Dupixent Pen100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Evaluation of Response to Ritlecitinib Treatment Based on SALT Improvement Scores in Patients with Alopecia Areata: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study
SKIN The Journal of Cutaneous Medicine
2023 - Leser Trelat Sign
StatPearls
2021 - Erythema Elevatum Diutinum
StatPearls
2019
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Robert Modlin, MD
University of California, Los Angeles
Heidi Kong, MD
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Jon Hanifin, MD
Oregon Health & Science University (OHSU)
Victoria Werth, MD
Perelman School of Medicine at the University of Pennsylvania
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”